Lumipulse immunoassays

Manufactured by Fujirebio

Sourced in Belgium

Lumipulse immunoassays are a range of automated laboratory diagnostic tests manufactured by Fujirebio. These tests utilize chemiluminescent technology to detect and measure specific analytes in patient samples. The core function of Lumipulse immunoassays is to provide quantitative analytical results for clinical decision-making.

Automatically generated - may contain errors

Lab products found in correlation

Simoa hd x platform, by Quanterix (1 mentions)

Spelling variants of this product

Lumipulse chemiluminescent immunoassay (4 citations)

2 protocols using lumipulse immunoassays

Multimodal Biomarker Assessment of Alzheimer's

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Amyloid β plaque deposition was assessed using a [¹¹C] Pittsburgh Compound B (PiB) PET tracer. PET data were analyzed from a 30-minute acquisition window beginning 40 min after a bolus injection of approximately 15 mCi of PiB. All PiB PET scans were processed with the PET Unified Pipeline (PUP) [35 (link)], including conventional processing steps and partial volume correction with a regional spread function (RSF). Standardized uptake value ratios (SUVR) summarized PiB tracer binding in previously-defined summary regions, including bilateral precuneus, prefrontal cortex, gyrus rectus, and lateral temporal regions, using the cerebellum as a reference region [35 (link)].
Cerebrospinal fluid (CSF) samples were collected via lumbar puncture under fasting conditions [17 (link)]. CSF amyloid β42 (Aβ42), amyloid β40 (Aβ40), and phosphorylated tau-181 (pTau) were measured with Lumipulse immunoassays (Fujirebio). Aβ42 and pTau estimates were normalized for individual differences in CSF production rates by forming a ratio with Aβ40 as the denominator [36 (link), 37 ]. Neurofilament-light-chain (NfL) was measured with a Simoa HD-X platform (Quanterix).
Blood samples were collected via venipuncture under fasting conditions [38 (link)]. Plasma pTau and NfL were measured on a Simoa HD-X platform (Quanterix).

Millar P.R., Gordon B.A., Wisch J.K., Schultz S.A., Benzinger T.L., Cruchaga C., Hassenstab J.J., Ibanez L., Karch C., Llibre-Guerra J.J., Morris J.C., Perrin R.J., Supnet-Bell C., Xiong C., Allegri R.F., Berman S.B., Chhatwal J.P., Chrem Mendez P.A., Day G.S., Hofmann A., Ikeuchi T., Jucker M., Lee J.H., Levin J., Lopera F., Niimi Y., Sánchez-González V.J., Schofield P.R., Sosa-Ortiz A.L., Vöglein J., Bateman R.J., Ances B.M, & McDade E.M. (2023). Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease. Molecular Neurodegeneration, 18, 98.

+ Open protocol

+ Expand

Alzheimer's Disease Biomarkers in Cognitive Decline

Check if the same lab product or an alternative is used in the 5 most similar protocols

This is a cross-sectional study that included participants of the BIODEGMAR cohort, an observational longitudinal study that enrolls individuals with cognitive decline and/or neurodegenerative diseases visiting the Cognitive Decline and Movement Disorders Unit of Hospital del Mar (Barcelona, Spain).^{21 (link)} Participants from the BIODEGMAR cohort donated a blood sample and underwent a detailed neurological and neuropsychological evaluation, a brain magnetic resonance imaging (MRI) study, and a lumbar puncture. All participants included in the present study had a Global Deterioration Score (GDS) >1.^{22 (link)} Core AD CSF biomarkers (Aβ42/40, p-tau, and t-tau) were measured with Lumipulse immunoassays (Fujirebio, Belgium). Participants were classified as AD CSF profile if the CSF Aβ42/p-tau ratio was <10.25.^{21 (link)} A comprehensive description of the BIODEGMAR cohort, the inclusion and exclusion criteria, the core AD CSF biomarkers measurements, and cutoffs determination can be found in the Methods section in the supporting information.

Ashton N.J., Puig-Pijoan A., Milà-Alomà M., Fernández-Lebrero A., García-Escobar G., González-Ortiz F., Kac P.R., Brum W.S., Benedet A.L., Lantero-Rodriguez J., Day T.A., Vanbrabant J., Stoops E., Vanmechelen E., Triana-Baltzer G., Moughadam S., Kolb H., Ortiz-Romero P., Karikari T.K., Minguillon C., Sánchez J.J., Navalpotro-Gómez I., Grau-Rivera O., Manero R.M., Puente-Periz V., de la Torre R., Roquer J., Dage J.L., Zetterberg H., Blennow K, & Suárez-Calvet M. (2022). Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimer's & dementia : the journal of the Alzheimer's Association, 19(5), 1913-1924.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!